Cybersecurity company Tenable has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. Tenable plans on listing the stock on the NASDAQ under the ticker symbol "TENB." Morgan Stanley, J.P. Morgan, Allen & Company LLC and Deutsche Bank will serve as the lead underwriters. Tenable's backers include Accel, In-Q-Tel and Insight Venture Partners, according to Crunchbase.
Monaco-based GoodBulk, an owner and operator of dry bulk vessels, has pulled its IPO due to "adverse market conditions." The company had planned trading the stock on the NASDAQ. GoodBulk’s backers include CarVal Investors and Lantern Asset Management.
IPL Plastics Inc, a Montréal-based packaging solutions provider, has raised $178 million for its IPO after pricing its 13.2 million shares at $13.50 per share. The company could raise as much as $205 million if the issue’s greenshoe option is exercised in full. The stock began trading June 28, 2018 on the Toronto Stock Exchange under the ticker symbol IPLP. IPL Plastics's pre-IPO backers were Caisse de dépôt et placement du Québec and Fonds de solidarité FTQ. As reported by PE Hub Canada earlier this month, the Caisse and the Fonds will continue to hold stakes with the IPO’s close.
Lexington, Massachusetts-based Translate Bio Inc, a messenger RNA therapeutics company, has raised about $121.6 million for its IPO after pricing its 9.35 million shares at $13 per share. The stock began trading June 28, 2018 on the NASDAQ under the ticker symbol "TBIO." Citigroup, Leerink Partners and Evercore ISI are the lead underwriters. Translate Bio's pre-IPO backers include M Ventures, SR One, Leerink Partners, Partners Innovation Fund and Rock Springs Capital, according to Crunchbase.
BJ's Wholesale Club Holdings Inc said June 27 that it priced its IPO at 37.5 million shares at $17 each, the top of its $15 to $17 price range. The company is expected to begin trading on the NYSE on June 28 under the ticker “BJ.” BJ’s is backed by CVC Capital Partners and Leonard Green & Partners.
Cambridge, Massachusetts-based Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, has debuted its IPO after pricing its 6.25 million shares at $16 per share. The stock began trading June 27, 2018 on the NASDAQ under the ticker symbol "NTGN." Morgan Stanley, BofA Merrill Lynch and Mizuho Securities are the lead underwriters. Neon Therapeutics' pre-IPO backers include Partner Fund Management, Third Rock Ventures, Access Industries, Fidelity Management & Research Company, Wellington Management Company, Inbio Ventures and Nextech Invest.
China Renaissance Group, an investment bank led by one of the country’s most famed rainmakers, aims to raise as much as $800 million in a Hong Kong IPO, sources told Reuters.
London-based Autolus, a biopharmaceutical company focused on developing and commercializing T-cell therapies, has raised about $150 million after pricing 8.8 million shares of its IPO at $17 per share. The stock began trading June 22, 2018 on the NASDAQ under the ticker symbol “AUTL.” Goldman Sachs and Jefferies LLC are the lead underwriters. Autolus’pre-IPO backers include Arix Bioscience plc, Cormorant Asset Management, Nextech Invest, Syncona and Woodford Investment Management.
IPL Plastics Inc, a Montréal-based packaging solutions provider, has finalized the pricing of its proposed initial public offering of common shares in Canada. The company plans to sell shares at $13.50 per unit, generating proceeds of $178.2 million or as much as $204.9 million if the issue's greenshoe option is exercised in full. The IPO is expected to close on June 28, when shares will begin trading on the Toronto Stock Exchange under the symbol IPLP. IPL Plastics has been backed by Caisse de dépôt et placement du Québec (CDPQ) and Fonds de solidarité FTQ since 2015. As reported by PE Hub Canada earlier this month, CDPQ and the Fonds will continue to hold stakes with the IPO's close.
Chicago-based Xeris Pharmaceuticals Inc, a specialty pharmaceutical company, has raised $85.5 million for its IPO after pricing its 5.7 million shares at $15 per share. The stock began trading June 21, 2018 on the NASDAQ under the ticker symbol "XERS." Jefferies, Leerink Partners, RBC Capital Markets and Mizuho Securities are the lead underwriters. Xeris Pharmaceuticals' pre-IPO backers include Merieux Developpement, Wild Basin Investments, Deerfield, Redmile Group and Texas Venture Labs, according to Crunchbase.